Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates.
Blocking proprotein convertase subtilisin kexin type 9 (PCSK9) binding to low-density lipoprotein receptor (LDLR) can profoundly lower plasma LDL levels. Two anti-PCKS9 monoclonal antibodies (mAbs), alirocumab and evolocumab, were approved by the FDA in 2015. The recommended dose is 75 mg to 150 mg...
Main Authors: | Yijun Shen, Hua Li, Li Zhao, Gang Li, Ben Chen, Qingsong Guo, Bei Gao, Jinsong Wu, Tong Yang, Li Jin, Yong Su |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5560549?pdf=render |
Similar Items
-
PCSK9 monoclonal antibodies: An overview
by: Rasha Kaddoura, et al.
Published: (2020-01-01) -
PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
by: EBioMedicine
Published: (2015-12-01) -
The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
by: Tanawan Kongmalai, et al.
Published: (2021-02-01) -
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
by: Krista M. Schroeder, et al.
Published: (2015-11-01) -
Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
by: Nathan D. Wong, et al.
Published: (2019-03-01)